Search Results

Business

Boehringer Ingelheim and Enleofen Ink $1 Billion+ Fibrosis Deal

In the deal, Boehringer acquired worldwide exclusive rights to Enleofen’s preclinical interleukein-11 (IL-11) platform.

January 9, 2020

·

3 min read

·

Mark Terry

Business

Abzena Release: Novel Antibodies Against a Ground-Breaking New Target for the Treatment of Cardiovascular Fibrosis Developed by Enleofen Bio, With Support From Abzena, Featured in ‘Nature’ Article

Abzena plc, the life sciences group providing services and technologies to enable the development and manufacture of biopharmaceutical products, works with Enleofen Bio, to develop first-in-class antibody therapeutics for the treatment of fibrotic human diseases.

November 14, 2017

·

4 min read

Business

Boehringer Ingelheim Partners with Enleofen to Develop First-in-Class Anti-IL-11 Therapies for a Range of Fibrotic Diseases

Acquisition of worldwide exclusive rights adds extensive anti-IL-11 platform to Boehringer Ingelheim pipeline portfolio

January 9, 2020

·

3 min read

Drug Development

Scientists Identify New Therapeutic Target for Fatty Liver Disease

Enleofen Bio announced the publication of promising data from a preclinical study of a novel therapy targeting a severe form of fatty liver disease.

May 22, 2019

·

3 min read

Drug Development

Boehringer Ingelheim Begins Clinical Development of First-In-Class Treatment for Fibrotic Diseases

Boehringer Ingelheim announced today that it has launched clinical development of its first-in-class IL-11 inhibitor antibody BI 765423 with a Phase 1 study ( NCT05658107 ) to assess the safety, tolerability, and pharmacokinetics in healthy volunteers.

May 9, 2023

·

3 min read

Enleofen Release: Publication in Leading Scientific Journal ‘Nature’ by Singaporean Research Team Highlights Groundbreaking New Target for the Treatment of Cardiovascular Fibrosis

The work, led by Stuart Cook and Sebastian Schafer, was performed by a team of scientists at Duke-NUS and NHCS.

November 14, 2017

·

2 min read

Business

Development of first-in-class antibody therapeutics and new partnership bring hope to patients with fibrotic and inflammatory diseases

Clinicians and scientists from National Heart Centre Singapore, Duke-NUS Medical School’s Cardiovascular & Metabolic Disorders Programme (CVMD) and SingHealth Duke-NUS Academic Medical Centre (AMC)s’ discovery of a key driver of fibrosis and inflammation in human diseases is now moving rapidly toward the clinic.

January 9, 2020

·

5 min read

FDA

FDA Approves Boehringer Ingelheim’s Ofev for Wider Use in Lung Disease

The U.S. Food and Drug Administration approved Boehringer Ingelheim’s Ofev (nintedanib) for patients with chronic fibrosing interstitial lung diseases with a progressive phenotype.

March 10, 2020

·

2 min read

·

Mark Terry